Carisma Therapeutics Inc. (CARM NASDAQ) stock market data APIs
$0.0004
0(0%)
as of May 4, 2026
Try our APIs with
free plan!
Carisma Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Prev. Close
0.0004
Open
0.0004
High
0.0004
Low
0.0004
52 wk Range
0.0001-1.27
Market Cap
20 922
P/E Ratio
0.0026
Shares Outstanding
41 845 K
Revenue
52 632 K
EPS
1.07
Beta
1.313
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Carisma Therapeutics Inc. data using free add-ons & libraries
Get Carisma Therapeutics Inc. Fundamental Data
Carisma Therapeutics Inc. Fundamental data includes:
- Net Revenue: 52 632 K
- EBITDA: 14 177 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Carisma Therapeutics Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.57
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Carisma Therapeutics Inc. News
New
Carmila: First-Quarter 2026 Financial Information
Continued value creation through the three growth engines Organic growth in net rental income of 1.2% in first-quarter 2026, outpacing indexation by 80 basis points, in line with targets Investment g...
Carmila: Availability of Documents for the Ordinary and Extraordinary Shareholder Meeting on 13 May 2026
PARIS, April 22, 2026--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM) shareholders are invited to participate in Carmila’s Ordinary and Extraordinary Shareholder Meeting to be held on Wedne...
Carmila Makes its 2025 Universal Registration Document Available
PARIS, April 01, 2026--(BUSINESS WIRE)--Regulatory News: Carmila (Euronext Paris: CARM) filed its 2025 Universal Registration Document with the French Financial Markets Authority (AMF) on 31 March 20...
CARMILA: Information Concerning the Total Number of Voting Rights and Share
provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement généralde l’Autorité des marchés financiers (General regulation of t...
Get Carisma Therapeutics Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
